Haemophilia: open trials in China

30 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT07416604
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Trial Treatment · Phase 3 · Hoffmann-La Roche
Peking Union Medical College Hospital - East Campus, Beijing · Chengdu Women's and Children's Central Hospital, Chengdu · Fujian Medical University Union Hospital, Fuzhou · Nanfang Hospital, Southern Medical University, Guangzhou · Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-11-03
NCT03961243
Lentiviral FIX Gene Therapy
Trial Treatment · Phase 1 · Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-immune Medical Institute, Shenzhen
Registry updated 2026-11-02
NCT03217032
Lentiviral FVIII Gene Therapy
Trial Treatment · Phase 1 · Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-immune Medical Institute, Shenzhen
Registry updated 2026-10-30
NCT07285460
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Trial Treatment · Phase 3 · Sanofi
Beijing · Wuhan
Registry updated 2026-10-27
NCT05145127
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Trial Treatment · Phase 3 · Pfizer
Beijing Children's Hospital, Capital Medical University, Beijing · Nanfang Hospital, Southern Medical University, Guangzhou · The Affiliated Hospital of Guizhou Medical University, Guiyang · Jiangxi Provincial People's Hospital, Nanchang · Institute of hematology&blood disease hospital, Tianjin · Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Registry updated 2026-10-26
NCT07416526
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Trial Treatment · Phase 3 · Hoffmann-La Roche
Peking University People's Hospital, Beijing
Registry updated 2026-10-26
NCT05611801
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Trial Treatment · Phase 3 · Pfizer
Beijing Children's Hospital, Capital Medical University, Beijing · Southern Medical University Nanfang Hospital, Guangzhou · The Affiliated Hospital of Guizhou Medical University, Guiyang · Jiangxi Provincial People's Hospital, Nanchang · Institute of hematology&blood disease hospital, Tianjin · Tongji Hospital of Tongji Medical College of HUST/Pediatric Hematology Department Pharmacy, Wuhan · Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Registry updated 2026-10-14
NCT07847697
A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10
Trial Treatment · Phase 1 · Sinocelltech Ltd.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-09-29
NCT07789587
A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A
Trial Treatment · Institute of Hematology & Blood Diseases Hospital, China
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin
Registry updated 2026-08-27
NCT07788469
A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A
Trial Treatment · Institute of Hematology & Blood Diseases Hospital, China
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin
Registry updated 2026-08-26
NCT07644832
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
Trial Treatment · Phase 1/2 · Shanghai RAAS Blood Products Co., Ltd.
Xiangya Hospital of Central South University, Changsha · The First Affiliated Hospital of University of Science and Technology of China, Hefei · Jinan Central Hospital, Jinan · The First Hospital of Lanzhou University, Lanzhou · Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai · The Second Hospital of Shanxi Medical University, Taiyuan · Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin · Xian Central Hospital, Xi'an · Zhengzhou People's Hospital, Zhengzhou
Registry updated 2026-06-12
NCT06992076
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
Research · Institute of Hematology & Blood Diseases Hospital, China
Institute of haematology and Blood diseases hospital, Tianjin · The First Affiliated hospital of Xiamen University, Xiamen
Registry updated 2026-04-29
NCT07545395
Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
Trial Treatment · Phase 3 · Suzhou Alphamab Co., Ltd.
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-04-22
NCT06111638
Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
Trial Treatment · Phase 2/3 · Shanghai Xinzhi BioMed Co., Ltd.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing · Xiangya Hospital Central South University, Changsha · Sichuan Provincial People's Hospital, Chengde · Southern Hospital, Southern Medical University, Guangzhou · Affiliated Hospital of Guizhou Medical University, Guiyang · The Second Affiliated Hospital of Kunming Medical University, Kunming · The First Affiliated Hospital of Soochow University, Suzhou · Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin · Wuhan Union Hospital Affiliated to Huazhong University of Science and Technology, Wuhan · The Affiliated Hospital of Northwest University Xi'an No.3 Hospital, Xi’an
Registry updated 2026-03-17
NCT07437404
Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
Trial Treatment · Phase 3 · Sinocelltech Ltd.
Beijing Children's Hospital, Beijing
Registry updated 2026-02-27
NCT04645199
National Longitudinal Cohort of Hematological Diseases
Research · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, Tianjin
Registry updated 2026-02-12
NCT07406139
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）
Trial Treatment · Phase 4 · Institute of Hematology & Blood Diseases Hospital, China
Institute of haematology and Blood diseases hospital, Tianjin
Registry updated 2026-02-12
NCT06833983
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
Trial Treatment · Phase 3 · Gritgen Therapeutics Co., Ltd.
Peking Union Medical College Hospital, Beijing · Xiangya Hospital of Central South University, Changsha · Nanfang Hospital, Southern Medical University, Guangzhou · Anhui Provincial Hospital, Hefei · Central Hospital Affiliated to Shandong First Medical University, Jinan · The Second Affiliated Hospital of Kunming Medical University, Kunming · First Hospital of Lanzhou University, Lanzhou · Jiangxi Provincial People's Hospital, Nanchang · Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing · North China University of Science and Technology Affiliated Hospital, Tangshan · Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · Henan Cancer Hospital, Zhengzhou
Registry updated 2025-12-09
NCT07205523
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Research · Yigeng Cao,MD,PhD
Affiliated Hospital of Qinghai University, Xining
Registry updated 2025-10-03
NCT05849740
An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A
Trial Treatment · Phase 4 · Institute of Hematology & Blood Diseases Hospital, China
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin
Registry updated 2025-08-05
NCT04728841
Gene Therapy for Chinese Hemophilia A
Trial Treatment · Institute of Hematology & Blood Diseases Hospital, China
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin
Registry updated 2025-08-01
NCT06864975
Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
Trial Treatment · Phase 4 · Runhui WU
Beijing Children's hospitial, Beijing
Registry updated 2025-03-07
NCT05630651
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
Trial Treatment · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, Tianjin
Registry updated 2025-02-24
NCT05641610
A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
Trial Treatment · Phase 1/2 · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, Tianjin
Registry updated 2025-02-24
NCT05888870
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
Trial Treatment · Phase 4 · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
Registry updated 2025-02-24

All Haemophilia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error